| R |
|
RAC1 IS AN EFFECTOR OF THE GPVI SIGNALING CASCADE IN PLATELETS
|
| Pozgajova M., Strehl A., Pleines I., Chrostek A., Elvers M., May F., Brakebusch C., Nieswandt B. |
| |
|
RADIOISOTOPE SYNOVECTOMY WITH RHENIUM 186 FOR TREATMENT OF HEMOPHILIC SYNOVITIS
|
| Kavakli K., Aydogdu S., Taner M., Duman Y., Capaci K., Balkan C., Yilmaz D., Oktay A., Saydam G. |
| |
|
RADIOSYNOVECTOMY WITH YTRIUM-90 AND RHENIUM-186 IN HEMOPHILIC ARTHROPATY
|
| Aydogan G., Salcioglu Z., Pekun F., Turkkan E., Altun M., Ozulker T., Sen H., Akici F. |
| |
|
RADIOSYNOVIORTHESIS IS NECESSARY IN HEMOPHILIC PATIENTS DESPITE PROHYLAXIS
|
| Rodriguez-Merchan E.C., de la Corte-Rodriguez H., Romero-Garrido J.A., Quintana-Molina M., Lopez-Cabarcos C., Alvarez-Roman M.T., Jimenez-Yuste V., Fernandez-Bello I., Jimenez-Caballero E., Hernandez-Navarro F. |
| |
|
RAISED CIRCULATING ENDOTHELIAL CELLS IN RHEUMATOID AND EARLY ARTHRITIS
|
| Blann A.D., Foster W., Shantilisa E., Carruthers D., Lip G. |
| |
|
RAISED LEVELS OF CD39 IN LEUCOCYTOSIS RESULT IN MARKED INHIBITION OF ADP-INDUCED PLATELET AGGREGATION VIA RAPID ADP HYDROLYSIS
|
| Heptinstall S., Myers B., Fox S.C., Glenn J.R., Johnson A.J., White A.E. |
| |
|
RANDOMISED TRIAL OF ANTICOAGULATION VERSUS ANTIPLATELET THERAPY AS PRIMARY THROMBOPROPHYLAXIS FOLLOWING FONTAN SURGERY IN CHILDREN.THE FONTAN A STUDY
|
| Monagle P. |
| |
|
RANDOMISED, OPEN, PROSPECTIVE, MULTICENTER PILOT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ACTIVATED RECOMBINANT FACTOR VIIA (NOVOSEVEN) IN ACUTE INTRACEREBRAL HAEMORRHAGE IN PATIENTS TREATED WITH ORAL ANTICOAGULANT OR ANTIPLATELET AGENTS
|
| Iorio A., Marchesini E., Falcou A., Caso V., Pastorello M., Tiscione V., Ballarino P., Altomonte F., Baldi G., Agnelli G., Toni D. |
| |
|
RAP1B IS REQUIRED FOR NORMAL ANGIOGENESIS AND MAPK SIGNALING IN ENDOTHELIAL CELLS
|
| Chrzanowska-Wodnicka M., White G.C., Kraus A.E., VanSluys J. |
| |
|
RAPID INCREASE OF EXPRESSION OF INDUCIBLE CYCLOOXYGENASE (COX-2) IN MONOCYTES OF PATIENTS WITH TYPE II DIABETES MELLITUS (T2DM) EXPOSED IN VIVO TO HYPERGLYCEMIC SPIKES
|
| Corazzi T., De Angelis M., Busciantella N., Cecchetti L., Bolli G.B., Gresele P. |
| |
|
RAPID INCREASE OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH HAEMOPHILIA AND CHRONIC HCV- INFECTION
|
| von Auer C., Heinsdorf S., Krause M., Miesbach W., Scharrer I. |
| |
|
RAPID LIGAND-INDUCED DIMERIZATION OF PLATELET GLYCOPROTEIN VI
|
| Arthur J.F., Gardiner E.E., Shen Y., Kahn M.L., Berndt M.C., Andrews R.K. |
| |
|
RARE ANTIGENS IN NEONATAL ALLOIMMUNE THROMBOCYTOPENIA
|
| Peterson J.A., Gitter M.L., Pietz B.C., Johnson S.C., Balthazor S.M., Aster R.H. |
| |
|
RARE COAGULATION DISORDERS IN ISFAHAN HEMOPHILIA CENTER
|
| Hoorfar H., Hadipour M., Pasalar P. |
| |
|
RATE OF DE NOVO VWF MUTATIONS IN PATIENTS HISTORICALLY DIAGNOSED WITH TYPE 1 VWD IN THE EUROPEAN STUDY, MOLECULAR AND CLINICAL MARKERS FOR THE DIAGNOSIS AND MANAGEMENT OF TYPE 1 VWD (MCMDM-1VWD)
|
| Goodeve A., Castaman G., Rodeghiero F., Federici A.B., Batlle J., Meyer D., Mazurier C., Goudemand J., Eikenboom J., Schneppenheim R., Budde U., Ingerslev J., Habart D., Vorlova Z., Holmberg L., Lethagen S., Pasi J., Hill F., Hashemi Soteh M., Baronciani L., Hallden C., Guilliatt A., Lester W., Peake I. |
| |
|
REACTIVE OXYGEN SPECIES DERIVED FROM PLATELETS REDUCE THE ACTION OF NITRIC OXIDE
|
| Grenegard M., Lindstrom E.G. |
| |
|
REACTIVE OXYGEN SPECIES GENERATION IS REQUIRED FOR THROMBIN-INDUCED PLATELET APOPTOSIS
|
| Lopez J.J., Redondo P.C., Pariente J.A., Salido G.M., Rosado J.A. |
| |
|
REAL EFFECT OF WARFARIN THERAPY PREVENTING STROKE IN PATIENTS WITH ATRIAL FIBRILLATION
|
| Cotrina R.Y. |
| |
|
RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS (RAGE) EXPRESSED ON HEK293 CELLS BINDS OXIDIZED LOW DENSITY LIPOPROTEINS (OXLDL)
|
| Martin J., McDermott-Roe C., Morser K., McGregor J. |
| |
|
RECOMBINANT ACTIVATED FACTOR VII (RFVIIA) IN THE TREATMENT OF CRITICAL HAEMORRHAGE. A SINGLE CENTRE EXPERIENCE
|
| Lopez Fernandez M., Amor Otero M., Andón Saavedra C., Batlle Fonrodona J. |
| |
|
RECOMBINANT ACTIVATED FACTOR VII IN THE TREATMENT OF ACUTE POST PARTUM HEMORRHAGE: THE ITALIAN REGISTRY
|
| Barillari G., Frigo M., Malacarne S., Ulrich O., Farnia G. |
| |
|
RECOMBINANT ACTIVATED FACTOR VII VS. ACTIVATED PROTHROMBIN COMPLEX CONCENTRATE AS ON-DEMAND TREATMENT OF JOINT BLEEDS IN HEMOPHILIACS WITH INHIBITORS: A SYSTEMATIC LITERATURE REVIEW
|
| McCraken F., Thurston S., Joshi A., Heeg B., Verheggen B., Botteman M.F., van Hout B. |
| |
|
RECOMBINANT ACTIVATED HUMAN FACTOR VII (FVIIA) BINDS TO THE ENDOTHELIAL PROTEIN C RECEPTOR (EPCR) ON HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS (HUVEC)
|
| Steinoe A., Sorensen B.B., Stennicke H.R. |
| |
|
RECOMBINANT BBETA-LYS448 IS ASSOCIATED WITH SIGNIFICANT CHANGES IN FIBRIN STRUCTURE AND CLOT RIGIDITY
|
| Ajjan R., Standeven K.F., Harrand R., Phoenix F., Dolling S., Grant P.J., Ariens R.A.S. |
| |
|
RECOMBINANT COAGULATION FACTOR VIIA IN THERAPY OF MASSIVE POST-PARTUM BLEEDING AT PATIENT WITH IDIOPATHIC THROMBOCYTOPENIA (ITP)
|
| Fedorova T.A., Chernukha E.A., Puchko T.K., Rogachevskiy O.V. |
| |
|
RECOMBINANT FACTOR VIIA PARTIALLY REVERSES THE ANTICOAGULANT EFFECT OF HIGH-DOSE RIVAROXABAN A NOVEL, ORAL, DIRECT FACTOR XA INHIBITOR IN RATS
|
| Tinel H., Huetter J., Perzborn E. |
| |
|
RECOMBINANT FACTOR VIIA PARTIALLY REVERSES THE EFFECTS OF THE FACTOR XA INHIBITOR RIVAROXABAN ON THROMBIN GENERATION, BUT NOT THE EFFECTS OF THROMBIN INHIBITORS, IN VITRO
|
| Perzborn E., Harwardt M. |
| |
|
RECOMBINANT FVIIA USE IN THREE PRETERM NEONATES WITH DISSEMINATED INTRAVASCULAR COAGULATION
|
| Berrak S.G., Cakir B.F., Beker B.D., Canpolat C., Altuncu E., Bilgen H., Ozek E. |
| |
|
RECOMBINANT HUMAN ACTIVATED PROTEIN C (RHAPC) IN PIG-TO-PRIMATE XENOTRANSPLANTATION
|
| Tognin G., Boldrin M., Gavasso S., Seveso M., Baldan N., Calabrese F., Giacometti C., Bosio E., Zerbinati P., Fadin M., Castagnaro M., Busetto R., Dedja A., Cozzi E., Ancona E., Simioni P. |
| |
|
RECOMBINANT HUMAN HPA-1A ANTIBODIES FOR TREATMENT OF FETO-MATERNAL ALLO-IMMUNE THROMBOCYTOPENIA (FMAIT): PROOF OF PRINCIPLE IN AN IN VIVO MURINE MODEL
|
| Ghevaert C., Wilcox D., Fang J., Ouwehand W.H., Williamson L.M. |
| |
|
RECOMBINANT HUMAN PLASMIN PRODUCED IN LEMNA MINOR
|
| Brookhart G.L., Lounes K.C., Tomalski M.D., Humphries J.E., Kluft C., Meijer P., Radtke K.P. |
| |
|
RECOMBINANT HUMAN THROMBOMODULIN PROMOTES SMOOTH MUSCLE CELL MIGRATION
|
| Wu H., Chou F., Liu S., Shi G. |
| |
|
RECOMBINANT IL-11 INCREASES VWF AND VWFMRNA IN TYPE 1 VWD
|
| Jankowitz R.C., Chapman H., Merricks E., Kloos M., Dillow A., Nichols T.C., Ragni M.V. |
| |
|
RECOMBINANT THROMBOMODULIN DOES NOT CROSS REACT WITH ANTI-HEPARIN PLATELET FACTOR 4 ANTIBODIES. POTENTIAL IMPLICATION FOR ANTICOAGULATION OF HEPARIN-INDUCED THROMBOCYTOPENIA PATIENTS
|
| Fareed D., Hoppensteadt D., Walenga J.M., Jeske W.P., Bick R., Fareed J. |
| |
|
RECOMBINATION IN ENDOTHELIAL CELL PROTEIN C RECEPTOR GENE PROCR. INFERENCE FOR THROMBOPHILIC PATIENTS SCREENING
|
| Saposnik B., Lokajczyk A., Aiach M., Gandrille S. |
| |
|
RECOMBINATION IN ONE HAEMOPHILIA A FAMILY
|
| Lu Y., Wang X., Ding Q., Wang H. |
| |
|
RECURRENCE OF THE FACTOR VIII GENE R531H MUTATION IN 13 IRISH FAMILIES: EVIDENCE FOR A FOUNDER EFFECT
|
| Winter P.C., Egan H., McNulty O., Jones F., O'Donnell J., Jenkins V. |
| |
|
RECURRENT ARTERIAL THROMBOSIS WITH FACTOR V LEIDEN HOMOZYGOCY
|
| Bradstreet C., Delatte P., Bosschaerts T., Alonso I., Cantinieaux B., Hermans P. |
| |
|
RECURRENT DEEP VEIN THROMBOSIS (DVT) IS EXCLUDED BY A NEGATIVE D-DIMER OR SERIAL COMPRESSION ULTRASONOGRAPHY (CUS): RESULTS OF A MULTICENTER MANAGEMENT STUDY
|
| Bates S.M., Kearon C., Kahn S.R., Jim J., Crowther M.A., Gerdes V.E.A., Geerts W., Kovacs M.J., Weise-Kelly L., Ginsberg J.S. |
| |
|
RECURRENT VENOUS THROMBOEMBOLISM LINKED TO LOW PLASMA HDL
|
| Pecheniuk N.M., Deguchi H., Griffin J.H., Kyrle P.A., Eichinger S. |
| |
|
RECURRENT VENOUS THROMBOSIS OF THE UPPER EXTREMITY
|
| Flinterman L.E., Doggen C.J.M., Rosendaal F.R. |
| |
|
RED LASER RADIATION INCREASES PLATELET RESPONSE TO ADP
|
| Budnik I.A., Brill G.E., Gasparyan L.V. |
| |
|
REDIAGNOSIS OF PLATELET "SECRETION" DISORDERS BY SIMULTANEOUS MEASUREMENT OF AGGREGATION AND ATP SECRETION
|
| Dawood B.B., Wilde J., Watson S.P. |
| |
|
REDUCED ATHEROSCLEROTIC LESIONS IN P2Y1/APOE DOUBLE KNOCKOUT MICE
|
| Hechler B., Freund M., Ravanat C., Magnenat S., Cazenave J.P., Gachet C. |
| |
|
REDUCED BLEEDING TIME PROLONGATION FOR THE REVERSIBLE P2Y12 ANTAGONIST AZD6140 COMPARED WITH THE THIENOPYRIDINE, CLOPIDOGREL, IN BOTH A RAT AND DOG MODEL OF COMBINED THROMBOSIS AND HEMOSTASIS
|
| Björkman J.A., van Giezen J.J.J., Zachrisson H. |
| |
|
REDUCED CLOT PERMEABILITY AND SUSCEPTIBILITY TO LYSIS IN PATIENTS WITH ACUTE CORONARY SYNDROME: EFFECTS OF INFLAMMATION AND OXIDATIVE STRESS
|
| Undas A., Szuldrzynski K., Stepien E., Zalewski J., Godlewski J., Tracz W., Pasowicz M., Zmudka K. |
| |
|
REDUCED MORTALITY OF PERITONEAL SEPSIS IN FACTOR XI DEFICIENT MICE
|
| Tucker E.I., Gailani D., Cheng Q., Hanson S.R., Gruber A. |
| |
|
REDUCTION IN EMERGENCY DEPARTMENT VISITS BY PATIENTS ATTENDING AN ANTICOAGULATION CLINIC
|
| Whittaker P., Donovan J.L. |
| |
|
REDUCTION OF ANTI-FIX INHIBITOR TITER IN A HEMOPHILIA B PATIENT WITH CONTINUOUS USE OF APCC
|
| Watanabe T., Watanabe H., Onishi T., Okamura K., Kgami S., Yamada T., Kawano Y. |
| |
|
REDUCTION OF DIABETES-RELATED LIPID OXIDATIVE STRESS BY STATIN THERAPY AS MONITORED BY SERUM OXIDIZED LDL/B2GPI COMPLEX LEVELS
|
| Svanas G., Boisen M., Oottamasathein D., Matsuura E., Lopez L.R. |
| |
|
REDUNDANT AND NON-REDUNDANT ROLES FOR CLASSICAL PKC ISOFORMS IN THE REGULATION OF PLATELET FUNCTION
|
| Konopatskaya O., Molkentin J.D., Poole A.W. |
| |
|
REFERENCE RANGE OF PLATELET FUNCTION ANALYZER-100 CLOSURE TIMES IN HEALTHY CHINESE
|
| Lin J., Lai C., Kuo S., Shen M. |
| |
|
REFERENCE VALUES FOR THROMBOELASTOGRAPHY IN HEALTHY CHILDREN
|
| Monagle P., Chan K., Summerhayes R., Ignjatovic V. |
| |
|
REFORMULATED RECOMBINANT FACTOR IX: EFFICACY AND SAFETY IN PREVIOUSLY TREATED PATIENTS WITH MODERATELY SEVERE TO SEVERE HEMOPHILIA B
|
| Lambert T., Recht M., Valentino L., Powell J.S., Udata C., Sullivan S.T., Roth D.A. |
| |
|
REGULATION OF BLOOD COAGULATION BY THE PROTEIN C PATHWAY
|
| Dahlbäck B. |
| |
|
REGULATION OF BREAST CANCER CELL GROWTH, METASTASIS AND ANGIOGENESIS BY PROTEIN C INHIBITOR
|
| Hayashi T., Asanuma K., Yoshikawa T., Akita N., Nakagawa N., Hamada Y., Nishioka J., Kamada H., Ido M., Gabazza E.C., Uchida A., Suzuki K. |
| |
|
REGULATION OF DEVELOPMENT AND FUNCTION ENDOTHELIAL CELLS BY XENOGENIC IMMUNOGLOBULINS
|
| Rugal V.I., Rukavitsin O.A. |
| |
|
REGULATION OF INSULIN-LIKE GROWTH FACTOR 1 IN PLATELET ACTIVATION
|
| Kim S., Kunapuli S.P. |
| |
|
REGULATION OF PHOSPHODIESTERASE 3A IN HUMAN PLATELETS IS MEDIATED BY PROTEIN KINASE C
|
| Hunter R.W., Harthill J.E., MacKintosh C., Hers I. |
| |
|
REGULATION OF PLASMA VON WILLEBRAND FACTOR (VWF) BY MODIFIER GENES
|
| Shavit J.A., Lemmerhirt H.L., Ginsburg D. |
| |
|
REGULATION OF PLASMINOGEN ACTIVATOR ACTIVITY IN THE CENTRAL NERVOUS SYSTEM
|
| Lawrence D.A. |
| |
|
REGULATION OF PROTEIN C INHIBITOR (PCI) ACTIVITY BY OXIDIZED AND NEGATIVELY CHARGED PHOSPHOLIPIDS
|
| Malleier J.M., Oskolkova O., Bochkov V., Jerabek I., Sokolikova B., Perkmann T., Breuss J., Binder B.R., Geiger M. |
| |
|
REGULATION OF PROTEIN S EXPRESSION IN HEPATOCYTES AND SINUSOIDAL ENDOTHELIAL CELLS IN RATS WITH CIRRHOSIS
|
| Hayashi T., Fujii K., Kishiwada M., Nishioka J., Okamoto T., Gabazza E.C., Uemoto S., Suzuki K. |
| |
|
REGULATION OF THE PLATELET PROCOAGULANT RESPONSE
|
| Appleby J.A., Stephens J.C., Jones C.I., Garner S.F., Ouwehand W.H., Goodall A.H. |
| |
|
REGULATORY EFFECT OF ALPHA1-ACID GLYCOPROTEIN ON PAI-1 REDISTRIBUTION ON ENDOTHELIAL CELLS SURFACE
|
| Boncela J.M., Papiewska-Pajak I., Smolarczyk K., Cierniewski C.S. |
| |
|
RELATION BETWEEN ENDOTHELIAL AND PLATELETS MICROPARTICLES AND VENOUS THROMBOEMBOLISM: A CASE-CONTROL STUDY
|
| Spiezia L., Castelli M., Sanzari M., Numera V., Radu C., Chiriu A., Tognin G., Rossetto V., Plebani M., Pagnan A., Simioni P. |
| |
|
RELATION OF PLATELET-FIBRIN CLOT STRENGTH, PLATELET REACTIVITY, INFLAMMATION AND GROWTH FACTOR RELEASE TO THROMBOTIC RISK IN PATIENTS UNDERGOING STENTING
|
| Gurbel P.A., Bliden K.P., Kreutz R.P., DiChiara J., Tantry U.S. |
| |
|
RELATIONSHIP BETWEEN CIRCULATING THROMBOMODULIN LEVELS AND LATENT PROGRESSION OF ATHEROSCLEROSIS IN TYPE 2 DIABETIC PATIENTS
|
| Korzh O., Pavlova O., Lavrova E. |
| |
|
RELATIONSHIP BETWEEN ENDOTHELIAL HAEMOSTATIC MARKERS IN TYPE 2 DIABETIC PATIENTS
|
| Korzh O., Lavrova E., Pavlova O. |
| |
|
RELATIONSHIP BETWEEN INFLAMMATORY INDEXES ON ADMISSION AND DIAGNOSIS OF ACUTE AORTIC DISSECTION
|
| Ferroni P., Labbadia G., Rosa A., Martini F., Di Franco M., Bufi M., Vivino G., Palmirotta R., Bertazzoni G., Guadagni F., Basili S. |
| |
|
RELATIONSHIP BETWEEN OXIDATIVE STRESS, ENDOTHELIAL INJURY AND COAGULATION ACTIVATION IN ADVANCED CHRONIC HEART FAILURE
|
| Korzh I., Fedotova I. |
| |
|
RELATIONSHIP BETWEEN THE DIAMETER OF SOLEUS VEIN AND D-DIMER
|
| Hanzawa K., Okamoto T., Sato K., Hayashi J. |
| |
|
RELATIONSHIP OF PROCOAGULANT ACTIVITY TO PHOSPHATIDYLSERINE EXPOSURE ON IMMORTALIZED ACUTE PROMYELOCYTIC LEUKEMIA CELLS
|
| Shi J., Heegaard C.W., Rasmussen J.T., Gilbert G.E. |
| |
|
RELATIVE ANTICOAGULANT AND ANTITHROMBOTIC EFFECTS OF HEPARIN AND LOW MOLECULAR WEIGHT HEPARINS IN HUMAN AND FELINE BLOOD PLASMA. POTENTIAL THERAPEUTIC IMPLICATIONS
|
| McGeehan E., Azarafrooz F., Cera L., Buesing R., Hoppensteadt D., Fareed J. |
| |
|
RELEASE OF TISSUE FACTOR-BEARING MICROPARTICLES BY HUMAN DENDRITIC CELLS INDUCED BY STIMULATION OF MEMBRANE P2X7 RECEPTORS
|
| Baroni M., Pizzirani C., Pinotti M., Ferrari D., Adinolfi E., Calzavarini S., Caruso P., Di Virgilio F., Bernardi F. |
| |
|
RELEVANCE OF CA2+ ENTRY TO PLATELET AGGREGATION BY ACTIVATION OF THROMBIN RECEPTORS
|
| Jardin I., Redondo P.C., Ben-amor N., Bartegi A., Salido G.M., Rosado J.A. |
| |
|
REMOVAL OF HUMAN PARVOVIRUS B19 FROM FACTOR IX BY VIRUS FILTRATION
|
| Stagg S., Shackell A., Fernando S., Roberts P.L., Evans D., Feldman P.A. |
| |
|
REMOVAL OF PORCINE PARVOVIRUS SPIKED INTO SAMPLES OF HUMAN RECOMBINANT FACTOR VIII
|
| Jouvenot Y., Fordham D., Brisack K., Hesslein A., Liu S. |
| |
|
REMOVAL OF THE POSITIVE CHARGE BUT NOT THE HYDROPHOBIC STEM FROM LYSINE-222 IN ANTITHROMBIN III BETA-SHEET-A REDUCES FACTOR XA INHIBITION RATES AND INCREASES HEPARIN BINDING AFFINITY
|
| Jairajpuri M.A., Luis S.A., Lu A., Huntington J.A., Bock S.C. |
| |
|
RENAL ELIMINATION OF TINZAPARIN VERSUS ENOXAPARIN IN NORMAL VERSUS NEPHRECTOMIZED RATS
|
| Johansen K.B., Schroeder M., Lundtorp L., Mousa S.A. |
| |
|
RENAL IMPAIRMENT ESTIMATES TO PREDICT THE HAEMORRHAGE RISK IN 2170 PATIENTS TREATED BY HEPARIN. COCKCROFT-GAULT OR SIMPLIFIED MDRD?
|
| Phayphet M., Quenet S., Merli G., Levine M., Decousus H., Mottier D., Meyer G., Alamartine E., Mismetti P., Laporte S. |
| |
|
REPLACEMENT THERAPY WITH FIBRINOGEN CONCENTRATE: INDICATIONS AND ADEQUACY OF USE
|
| Lambert C.M., Hermans C.R. |
| |
|
REPLACING ORAL ANTICOAGULANTS WITH TINZAPARIN SODIUM IN PATIENTS UNDERGOING LAPAROSCOPIC CHOLECYSTECTOMY: SAFETY AND COST CONSIDERATIONS
|
| Volteas S.K., Babos A. |
| |
|
REPORT OF THE SC-VWF WORKING PARTY ON VWF ASSAYS IN VWD DIAGNOSES
|
| Lee C.A., Hubbard A., Sabin C.A., Budde U., Castaman G., Favaloro E.J., Friedman K., Mazurier C., Srivastava A., Weinstein M., Montgomery R., Lillicrap D., Federici A. |
| |
|
RESCUE IN VITRO OF SECRETION-DEFECTIVE FIBRINOGEN MUTANTS CAUSING AFIBRINOGENEMIA
|
| Vu D., Di Sanza C., Neerman-Arbez M. |
| |
|
RESEARCH IN CELL APOPTOSIS
|
| Appiah Kubi K., Appiah Kubi K. |
| |
|
RESIDUAL VENOUS OBSTRUCTION AND D-DIMER AS RISK FACTORS FOR RECURRENCE AFTER ANTICOAGULATION WITHDRAWAL FOR A FIRST IDIOPATHIC DEEP VEIN THROMBOSIS IN THE PROLONG STUDY
|
| Cosmi B., Legnani C., Tosetto A., Favaretto E., Palareti G. |
| |
|
RESIDUAL VENOUS THROMBOSIS AFTER 5-7 MONTHS OF ORAL ANTICOAGULANT (OAC) THERAPY AS A PREDICTOR OF SUBSEQUENT RECURRENT VENOUS THROMBOEMBOLISM VTE
|
| Rodger M.A., Kovacs M.J., Zeng W. |
| |
|
RESIDUES 311-325 ON THE HEAVY CHAIN OF FVA REPRESENT AN ACTIVATED PROTEIN C BINDING REGION
|
| Yegneswaran S., Kojima Y., Heeb M.J., Gale A.J., Griffin J.H. |
| |
|
RESISTANCE TO ANTI-PLATELET DRUGS: MOLECULAR MECHANISMS AND LABORATORY DETECTION
|
| Cattaneo M. |
| |
|
RESISTANCE TO OAC ASSOCIATED TO A NEW POINT MUTATION IN VKORC1 GENE
|
| Peoc'h K., Bal dit Sollier C., Pruvot S., Thomas S., Paulin D., Drouet L. |
| |
|
RESPONSE TO ASPIRIN AND CLOPIDOGREL IN HEALTHY MEN
|
| Madsen E.H., Schmidt E.B., Poulsen T.S., Kristensen S.R. |
| |
|
RESPONSE TO RITUXIMAB AND EPITOPE MAPPING OF INHIBITORY ANTIBODIES IN ACQUIRED HAEMOPHILIA
|
| Krause M., Koenigs C., Kessel C., Kirchmaier C., Kreuz W. |
| |
|
RESPONSE VARIABILITY TO ASPIRIN AS ASSESSED BY A PLATELET FUNCTION-ANALYZING DEVICE IN 5,007 SUBJECTS: A SYSTEMATIC REVIEW OF 40 STUDIES
|
| Crescente M., Di Castelnuovo A., Iacoviello L., Vermylen J., Cerletti C., de Gaetano G. |
| |
|
RESPONSIVENESS TO CLOPIDOGREL AND ASPIRIN AMONG PATIENTS WITH ACUTE CORONARY SYNDROME AS ASSESSED BY THE IMPACT-R [CONE AND PLATE(LET) ANALYZER]
|
| Shenkman B., Matetzky S., Hod H., Lubetsky A., Varon D., Savion N. |
| |
|
RESTORATION OF VON WILLEBRAND FACTOR FUNCTION IN A MURINE MODEL OF SEVERE VON WILLEBRAND DISEASE AFTER LIVER SPECIFIC GENE TRANSFER
|
| De Meyer S.F., Chuah M.K., VandenDriessche T., Vandeputte N., Pareyn I., Petrus I., Deckmyn H., Vanhoorelbeke K. |
| |
|
RESTORING INITIAL THROMBIN GENERATION DOES NOT NORMALIZE CUTANEOUS WOUND HEALING IN HEMOPHILIA B
|
| McDonald A.G., Brock J., Hedner U., Ezban M., Roberts H.R., Monroe D.M., Hoffman M. |
| |
|
RESULT DISCREPANCIES BETWEEN TWO LUPUS ANTICOAGULANT (LA) METHODS
|
| Arkin C.F. |
| |
|
RESULTS OF A ONE-YEAR REGISTRY OF BLEEDING COMPLICATIONS OF VITAMIN K ANTAGONIST THERAPY OUTSIDE A CONTROLLED POPULATION
|
| Halbritter K.M., Beyer J.J.B., Oettler W.W.O., Kleinstück B.B.K., Schellong S.S.M.S. |
| |
|
RETINAL CENTRAL ARTERY OCCLUSION AFTER 10 PILLS OF DROSPIRENONE CONTAINING PREPARATION (YASMIN)
|
| Girolami A., Vettore S., Scandellari R., Scarparo P., Girolami B. |
| |
|
RETRANSFUSION OF PERICARDIAL BLOOD DOES NOT TRIGGER SYSTEMIC COAGULATION DURING CARDIOPULMONARY BYPASS
|
| van den Goor J.M., Nieuwland R., Rutten P.M., Tijssen J.G., Hau C., Sturk A., Eijsman L., de Mol B.A. |
| |
|
RETRIEVABLE INFERIOR VENA CAVA (IVC) FILTERS IN A TERTIARY CARE POPULATION
|
| Alahmad A., Ramirez L.M., Sands M., Carman T.L. |
| |
|
RETRIEVABLE VENA CAVA FILTERS FOR SECONDARY PREVENTION OF PULMONARY EMBOLISM IN ORTHOPAEDIC SURGERY
|
| Rivron-Guillot K., Quenet S., Moulin N., Decousus H., Laporte S., Barral F.G., Mismetti P. |
| |
|
REVERSAL OF HYPERCHOLESTEROLEMIA PROTECTS AGAINST ARTERIAL THROMBOSIS IN ATHEROSCLEROTIC MICE
|
| Leo L., Wilson K.M., Miller J.D., Young S.G., Heistad D.D., Lentz S.R. |
| |
|
REVERSE: RECURRENT VENOUS THROMBOEMBOLISM (VTE) RISK STRATIFICATION EVALUATION: A PROSPECTIVE COHORT STUDY TO DEVELOP A CLINICAL PREDICTION RULE TO IDENTIFY LOW RISK PATIENTS WHO CAN DISCONTINUE ORAL ANTICOAGULANTS (OAC) 5-7 MONTHS AFTER TREATMENT FOR IDI
|
| Rodger M.A., Kovacs M.J. |
| |
|
REVERSE-HYBRIDIZATION-BASED GENETIC TESTING FOR THE PREDICTION OF ANTICOAGULANT DOSE REQUIREMENT
|
| Puehringer H., Stoellberger C., Krugluger W., Oberkanins C. |
| |
|
REVERSIBLE BIOTINYLATED OLIGOSACCHARIDES: A NEW APPROACH FOR A BETTER MANAGEMENT OF THE ANTICOAGULANT THERAPY
|
| Savi P., Herault J., Duchaussoy P., Millet L., Petitou M., Schaeffer P., Bono F., Herbert J. |
| |
|
RFVIIA IN THE TREATMENT OF GLANZMANN'S THROMBASTHENIA - CASE REPORT
|
| Marques L., Alves M., Antunes M., Diniz M. |
| |
|
RFVIIA IS EFFECTIVE ALTERNATIVE TO APCC IN PROPHYLAXIS OF BLEEDING DURING IMMUNE TOLERANCE PROTOCOL IN HAEMOPHILIAC WITH INHIBITOR
|
| Blatny J., Kohlerova S., Zapletal O., Fiamoli V., Penka M. |
| |
|
RGD-CONTAINING DENDROASPIN, RGD PEPTIDE AND DDM PEPTIDE INDUCE APOPTOSIS OF JURKAT CELLS
|
| Xia M., Lu D., Scully M., Lu X., Kakkar V. |
| |
|
RHOA IS ESSENTIAL FOR MEGAKARYOCYTE SURVIVAL IN VIVO
|
| Elvers M., Pleines I., van Hengel J., Brakebusch C., Nieswandt B. |
| |
|
RHOA/P160ROCK PLAYS AN IMPORTANT ROLE IN THE DENSE GRANULE RELEASE OF PLATELETS
|
| Jin J., Kim S., Mao Y., Kunapuli S.P. |
| |
|
RIGHT-TO-LEFT SHUNT, ATRIAL SEPTAL ANEURYSM AND THROMBOPHILIA IN PATIENTS WITH CRYPTOGENIC STROKE OR TIA VERSUS THOSE WITH VENOUS THROMBOEMBOLISM
|
| Migliaresi P., Palmieri V., Tufano A., De Simone C., Pezzullo S., Guida A., Somma C., Fiorica A., Vespoli C., Bonito M.C., Martino S., Cerbone A.M., Di Minno G., Celentano A. |
| |
|
RISK DETERMINANTS OF ARTERIAL THROMBOSIS INCREASE THE RISK OF INTRAUTERINE GROWTH RESTRICTION (IGR)
|
| Gerhardt A., Howe N., Kruessel J.S., Bender H.G., Scharf R.E., Zotz R.B. |
| |
|
RISK DETERMINANTS OF NONARTERITIC ISCHEMIC OPTIC NEUROPATHY (NAION)
|
| Zotz R.B., Finger C., Scharf R.E., Unsold R. |
| |
|
RISK FACTOR FOR ORAL ANTICOAGULANT TREATMENT OVERDOSE: A CASE CONTROL STUDY IN AN EMERGENCY UNIT
|
| Le Cam-Duchez V., Cadiou G., Benhamou Y., Varin R., Tiret I., Kerleau J.M., Veber B., Dieu B., Borg J.Y., Lévesque H. |
| |
|
RISK FACTOR PROFILE AND PATTERN OF USE OF MEDICATIONS IN JAPANESE PATIENTS AT A HIGH RISK OF CARDIOVASCULAR DIEASE: RESULTS FROM THE JAPAN THROMBOSIS REGISTRY FOR ATRIAL FIBRILLATION, CORONARY AND CEREBROVASCULAR DISEASE (J-TRACE)
|
| Goto S., Uchiyama S., Shimada K., Origasa H., Ikeda Y., J-TRACE Investigators |
| |
|
RISK FACTOR PROFILE ASSOCIATED WITH ICD IN SPANISH POPULATION
|
| García-Raso A., Moreno V.P., Drozdowskyj A., García-Bueno M.J., Sánchez C., García-Torres A., Mata R., Llamas P. |
| |
|
RISK FACTORS AND CLINICAL SIGNIFICANCE OF RESIDUAL PERFUSION DEFECTS AFTER SYMPTOMATIC PULMONARY EMBOLISM
|
| Roux A., Helley D., Wermert D., Fischer A., Sors H., Meyer G., Sanchez O. |
| |
|
RISK FACTORS AND OUTCOME OF PEDIATRIC THROMBOTIC EPISODES IN A SINGLE CENTER
|
| Gurgey A., Aytac S., Tavil B., Unal S., Gumruk F. |
| |
|
RISK FACTORS AND OUTCOME OF THROMBOEMBOLIC EVENTS IN CHILDREN UNDERGOING CARDIAC SURGERY
|
| Kuhle S., Atta N., Dyck J., Rebeyka I., Ross D., Mitchell L.G. |
| |
|
RISK FACTORS ASSOCIATED TO THE DEVELOPMENT OF PERIPHERAL ARTERIAL OBSTRUCTIVE DISEASE (PAOD)
|
| Mota A.P.L., Sousa M.O., Santos M.E.R.C., Lima L.M., Silva F.C.L., Carvalho M.G. |
| |
|
RISK FACTORS FOR CONCOMITANT VENOUS THROMBOEMBOLISM (VTE) IN PATIENTS WITH SUPERFICIAL THROMBOPHLEBITIS (ST): PRELIMINARY RESULTS OF THE POST STUDY
|
| Quéré I., Decousus H., Leizorovicz A. |
| |
|
RISK FACTORS FOR MORTALITY THREE MONTHS AFTER PULMONARY EMBOLISM
|
| Klok F.A., Nijkeuter M., Huisman M.V. |
| |
|
RISK FACTORS FOR THROMBOSIS IN CHILDREN
|
| Serbic O.M., Rakicevic L., Djordjevic V., Micic D., Veljkovic D., Vlahovic G., Gujanica Z., Rasovic N., Kuzmanovic M. |
| |
|
RISK FACTORS FOR THROMBOTIC THROMBOCYTOPENIC PURPURA: RESULTS OF THE SURVEILLANCE, EPIDEMIOLOGY AND RISK FACTORS FOR TTP (SERF-TTP) GROUP
|
| Zakarija A., Bandarenko N., Kwaan H., Pandey D., Cursio J., Tevar A., Buffie C., Weiss I., Ortel T., Winters J., Bennett C.L. |
| |
|
RISK FACTORS FOR VENOUS THROMBOEMBOLISM (VTE) AMONG ACTIVE CANCER PATIENTS: A POPULATION-BASED CASE-CONTROL STUDY
|
| Heit J.A., Marks R.S., Ashrani A.A., Petterson T.M., Bailey K.R., Melton III L.J. |
| |
|
RISK FACTORS IN WOMEN WITH GESTATIONAL DIABETES MELLITUS(GDM)
|
| Kashanian M., Fekrat M. |
| |
|
RISK FACTORS OF INCOMPLETE RECANALISATION AFTER DEEP VEIN THROMBOSIS
|
| Hirmerova J., Seidlerova J. |
| |
|
RISK FACTORS PREDICTIVE OF CARDIOVASCULAR EVENTS IN AN INCIDENT DIALYSIS COHORT: A ROLE FOR HOMOCYSTEINEMIA AND ITS MTHFR GENOTYPE
|
| Pernod G., Bosson J., Golshayan D., Barro C., Wauters J., Forneris G., Martinas G. |
| |
|
RISK MANAGEMENT IN THE DEVELOPMENT OF NEW ANTITHROMBOTIC DRUGS
|
| Leizorovicz A. |
| |
|
RISK OF A FIRST VENOUS OR ARTERIAL EVENT IN CARRIERS OF A FAMILIAL THROMBOPHILIC DEFECT
|
| Morange P.E., Aillaud M.F., Frère C., Brunet D., Barthet M.C., Morange S., Alessi M.C., Juhan-Vague I. |
| |
|
RISK OF BLEEDING IN VERY OLD ATRIAL FIBRILLATION PATIENTS ON WARFARIN: RELATIONSHIP WITH AGEING AND CHADS2 SCORE
|
| Poli D., Antonucci E., Mannini L., Abdullahi Said A., Rogolino A., Lucarini L., Falciani M., Abbate R., Gensini G., Prisco D. |
| |
|
RISK OF RECURRENCE AFTER A FIRST VENOUS THROMBOEMBOLIC EVENT IN YOUNG WOMEN
|
| Laczkovics C., Grafenhofer H., Kaider A., Quehenberger P., Simanek R., Mannhalter C., Lechner K., Pabinger I. |
| |
|
RISK OF RECURRENT VENOUS THROMBOEMBOLISM IN A SUBSEQUENT PREGNANCY IN WOMEN WITH A FIRST HISTORY OF VENOUS THROMBOSIS
|
| Gerhardt A., Scharf R.E., Zotz R.B. |
| |
|
RISK OF VENOUS THROMBOEMBOLISM (VTE) IN FIRST DEGREE RELATIVES (FDRS) OF PATIENTS WITH UNPROVOKED VTE WHO DO NOT HAVE FACTOR V LEIDEN (FVL) OR THE G20210A PROTHROMBIN GENE MUTATION (PGM)
|
| Couturaud F., Leroyer C., Julian J., Kahn S., Ginsberg J., Wells P., Douketis J., Mottier D., Kearon C. |
| |
|
RISK PROFILE OF PATIENTS WITH DVT DIAGNOSED IN AMBULATORY CARE - DATA FROM THE GERMAN TULIPA REGISTRY
|
| Schellong S.M., Gerlach H., Hach-Wunderle V., Rabe E., Riess H.B., Carnarius H., Banik N., Bauersachs R. |
| |
|
RISK STRATIFICATION FOR PULMONARY EMBOLISM
|
| Goldhaber S.Z. |
| |
|
RISK STRATIFICATION FOR VENOUS THROMBOEMBOLISM RECURRENCE
|
| Rodger M.A. |
| |
|
RISK STRATIFICATION OF RECURRENT VENOUS THROMBOEMBOLISM
|
| Zotz R.B., Gerhardt A., Segendorf H., Maruhn-Debowski B., Scharf R.E. |
| |
|
RISTOCETIN-INDUCED AGGREGATION OF HUMAN GPIBALPHA TRANSGENIC MICE IS INHIBITED BY ANTI-HUMAN GPIBALPHA ANTIBODIES IN THE PRESENCE OF HUMAN PLASMA
|
| Kim A.Y., Goel A., Tian X., Hui S.R., Biswas T.K., Ware J., Miller J.L. |
| |
|
RITUXIMAB IN THE TREATMENT OF FVIII INHIBITORS
|
| Leissinger C. |
| |
|
RITUXIMAB TREATMENT FOR MILD HEMOPHILIA A WITH INHIBITORS
|
| Sedano C., Pérez-Montes R., Ruiz M., Uresandi A., Colorado M., Moretó A., Iriondo A. |
| |
|
RIVAROXABAN A NOVEL, ORAL, DIRECT FACTOR XA INHIBITOR ENHANCED THE ANTITHROMBOTIC EFFECTS OF CLOPIDOGREL IN RATS
|
| Perzborn E., Fischer E., Lange U. |
| |
|
RIVAROXABAN AN ORAL, DIRECT FACTOR XA INHIBITOR BINDS RAPIDLY TO FACTOR XA
|
| Tersteegen A., Burkhardt N. |
| |
|
RIVAROXABAN AN ORAL, DIRECT FACTOR XA INHIBITOR HAS NO CLINICALLY RELEVANT INTERACTION WITH ACETYLSALICYLIC ACID OR NAPROXEN
|
| Kubitza D., Becka M., Mueck W., Zuehlsdorf M. |
| |
|
RIVAROXABAN AN ORAL, DIRECT FACTOR XA INHIBITOR INHIBITS TISSUE FACTOR-MEDIATED PLATELET AGGREGATION
|
| Perzborn E., Lange U. |
| |
|
RNA APTAMER-DIRECTED ANTICOAGULANT THERAPY
|
| Fortenberry Y.M., Whinna H.C., Monroe D.M., Church F.C. |
| |
|
RNAPC2, A NOVEL INHIBITOR OF TISSUE FACTOR/FACTOR VIIA COMPLEX, SUPPRESSES LIVER AND LUNG METASTASES IN MOUSE MODELS OF COLORECTAL CANCER
|
| Zhao J., Aguilar G., Deitcher S.R., Levy M.D., Funk W.D., Abo A. |
| |
|
RNAPC2, A NOVEL INHIBITOR OF TISSUE FACTOR/FACTOR VIIA COMPLEX, SYNERGIZES WITH 5-FU OR BEVACIZUMAB IN A MOUSE MODEL OF COLORECTAL CANCER
|
| Zhao J., Aguilar G., Deitcher S.R., Levy M.D., Funk W.D., Abo A. |
| |
|
ROLE OF 4G/5G PROMOTER POLYMORPHISM OF PLASMINOGEN ACTIVATOR INHIBITOR-1 GENE IN OUTCOME OF SEPSIS
|
| Fontana L., Cunto E., Nogueras C., Alonso B., San Juan J. |
| |
|
ROLE OF ANGIOPOIETIN(ANG)-1/TIE-2 SIGNALING PATHWAY FOR ANG-2 EXPRESSION IN VASCULAR ENDOTHELIAL CELLS
|
| Onimaru M., Yonemitsu Y., Fujii T., Sueishi K. |
| |
|
ROLE OF COLLAGEN IN PLATELET-DEPENDED CD4+ T CELL ADHESION
|
| Solpov A.V., Shenkman B., Vitkovsky Y.A. |
| |
|
ROLE OF D-DIMER IN COMBINATION WITH F1+2, RVO AND THROMBOPHILIA IN THE RISK OF RECURRENCE OF PATIENTS WITH A FIRST VTE EPISODE AFTER OAT WITHDRAWA
|
| Poli D., Antonucci E., Falciani M., Lucarini L., Evangelisti L., Pucci N., Poli S., Abbate R., Gensini G., Prisco D. |
| |
|
ROLE OF DISTINCT AMINO ACID RESIDUES IN THE INTERACTION OF SOLUBLE OR SURFACE-BOUND VON WILLEBRAND FACTOR A1 DOMAIN WITH PLATELETS
|
| Podda G.M., Roberts J.R., Habermann R., Ruggeri Z.M. |
| |
|
ROLE OF ELEVATED ALPHA2-MACROGLOBULIN REVISITED: RESULTS OF A CASE-CONTROL STUDY IN CHILDREN WITH SYMPTOMATIC THROMBOEMBOLISM
|
| Nowak-Gottl U., Beheiri A., Langer C., Düring C., Krümpel A., Thedieck S. |
| |
|
ROLE OF ENDOTHELIAL CELL-DERIVED MICROPARTICLES IN PATIENTS WITH CHRONIC HEART FAILURE
|
| Korzh O., Krasnokutskiy S. |
| |
|
ROLE OF FACTOR XII IN THROMBOSIS AND INFLAMMATION
|
| Renné T. |
| |
|
ROLE OF GLYCOPROTEIN IBA MOBILITY IN PLATELET DESTRUCTION AND FUNCTION
|
| van der Wal D.E., Verhoef S., Wu Y.P., Lenting P.J., Akkerman J.W.N. |
| |
|
ROLE OF HEMATOLOGIC AND SCREENING HEMOSTATIC PROFILE ON ADMISSION, IN PREDICTION OF DEVELOPMENT OF COMPLICATIONS IN HOSPITALIZED PATIENTS WITH DENGUE FEVER
|
| Murari M., Dewan U. |
| |
|
ROLE OF INDIVIDUAL AMINO ACID POSITIONS IN THE BINDING AND HYDROLYSIS OF GLUTAMINE-CONTAINING SUBSTRATES TO FACTOR XIIIA
|
| Maurer M.C., Cleary D.B. |
| |
|
ROLE OF INFLAMMATION IN MODULATING GRAFT TOLERANCE INDUCED BY MESENCHIMAL STEM CELLS
|
| Giusti B., Mazzanti B., Rossi L., Lapini I., Sestini I., Magi A., Torricelli F., Saccardi R., Fimiani M., Abbate R. |
| |
|
ROLE OF LIVER SINUSOIDAL ENDOTHELIAL CELLS IN ELIMINATION OF HEPARIN
|
| Øie C.I., McCourt P.A.G., Smedsrød B., Hansen J.B. |
| |
|
ROLE OF NOVEL LIPOPROTEIN-ASSOCIATED INFLAMMATORY MARKERS IN CORONARY ARTERY DISEASE: A PILOT STUDY
|
| Rao V.S., Natesha B.K., Renuka K.S., Kakkar V.V. |
| |
|
ROLE OF P38 MITOGEN ACTIVATED PROTEIN KINASE IN ANTIPHOSPHOLIPID ANTIBODY-MEDIATED THROMBOSIS AND ENDOTHELIAL CELL ACTIVATION
|
| Vega-Ostertag M., Romay-Penabad Z., Ferrara D., Colden-Stanfield M., Lui X., Pierangeli S.S. |
| |
|
ROLE OF PAR1 IN PROTECTIVE SIGNALING BY ACTIVATED PROTEIN C IN SYSTEMIC INFLAMMATION
|
| Feistritzer C., Schuepbach R.A., Fernandez J.A., Griffin J.H., Riewald M. |
| |
|
ROLE OF PI-3 KINASE BETA ISOFORM ON ADP-INDUCED PLATELET RESPONSES
|
| Garcia A.E., Kim S., Jackson S.P., Kunapuli S.P. |
| |
|
ROLE OF PLASMA FIBRONECTIN IN FIBRINOGEN/VWF-INDEPENDENT THROMBUS FORMATION
|
| Reheman A., Yang H., Bai X., Spring C.M., Wagner D.D., Fassler R., Gross P., Freedman J., Ni H. |
| |
|
ROLE OF PLATELET GLYCOPROTEIN IB-ALPHA POLYMORPHISM IN PLATELET REACTIVITY
|
| Pina-Cabral L., do Céu Monteiro M., Gonçalves M., Mesquita B., Almeida-Dias A., Dias D., Begoña Criado M. |
| |
|
ROLE OF PPAR-GAMMA ACTIVATION IN MEGAKARYOCYTOPOIESIS
|
| Pacienza N.A., Negrotto S., Pozner R.G., Malaver E., D'Atri L.P., Lazzari M.A., Torres O., Gomez R.M., Schattner M. |
| |
|
ROLE OF THE ALPHA-HELIX 163-170 IN FACTOR XA CATALYTIC ACTIVITY
|
| Levigne S., Thiec F., Cherel G., Fribourg C., Christophe O.D. |
| |
|
ROLE OF THE PROAPOPTOTIC BH3-ONLY PROTEIN BIM IN MEGAKARYOPOIESIS AND PLATELET PRODUCTION
|
| Kozuma Y., Kojima H., Yuki S., Nagasawa T. |
| |
|
ROLE OF THROMBOPHILIC RISK FACTORS IN PATIENTS WITH RETINAL VEIN OCCLUSION
|
| Krcova V., Slavik L., Rehak M., Faude S., Faude S., Wiedemann P., Fric E., Rehak J., Siegemund A. |
| |
|
ROLE OF THYROID HORMONE ANALOGS IN ANGIOGENESIS AND THE DEVELOPMENT OF COLLATERALS IN RABBIT HIND LIMB ISCHEMIA MODEL
|
| El Eter E., Rabee H., Alkayali A., Mousa S.A. |
| |
|
ROLE OF TISSUE REMODELLING IN HYPERTROPHIC MYOCARDIOPATHY
|
| Roldan V., Marin F., Gimeno J., Ruiz-Espejo F., Gonzalez-Conejero R., Garcia-Honrubia A., Vicente V. |
| |
|
ROLE OF TUBULIN-MICROTUBULES IN STORE-OPERATED CA2+ ENTRY IN HUMAN PLATELETS
|
| Redondo P.C., Sage S.O., Rosado J.A. |
| |
|
ROLES OF THE C-TERMINAL TYROSINE RESIDUES OF LAT IN GPVI-INDUCED PLATELET ACTIVATION; INSIGHT INTO THE MECHANISM OF PLC GAMMA2 ACTIVATION
|
| Severin S., Ragab A., Gratacap M.P., Aguado E., Malissen M., Jandrot-Perrus M., Malissen B., Ragab-Thomas J., Payrastre B. |
| |
|
ROSUVASTATIN EXERTS RENOPROTECTIVE EFFECTS IN STROKE-PRONE RATS BY MODULATING THE PLASMINOGEN/PLASMIN SYSTEM AND THE METALLOPROTEASES EXPRESSION
|
| Nobili E., Gianella A., Gelosa P., Sironi L., Bellosta S., Canavesi M., Abbate M., Zoja C., Tremoli E., Mussoni L. |
| |
|
ROTATION THROMBELASTOGRAPHY APPROACH DURING LIVER TRANSPLANTATION
|
| Stancheva A.G., Boncheva M.I., Georgieva M.D. |
| |
|
ROTEM THROMBELASTOMETRY ANALYTICAL CONTROL, VARIATION, AND VALIDATION USING A FROZEN PLATELET RICH PLASMA CONTROL AND ACTIVATION WITH MINUTE AMOUNTS OF TISSUE FACTOR
|
| Christiansen K., Norengaard L., Ingerslev J., Sørensen B. |
| |
|
ROTEM THROMBOELASTOMETRY IN OBSTETRIC: NEAR PATIENT-TEST AS AN EARLY PREDICTOR OF POST-PARTUM HEMORRHAGE (PPH)
|
| Bauters A., Ducloy-Bouthors A., Lejeune C., Provost N., Nobecourt C., Tournoys A., Jude B. |
| |
